semaglutide not being sold anymore selling - How is Hers still selling compoundedsemaglutide semaglutide shortage The Semaglutide Shortage is Officially Over: What This Means for Patients and Pharmacies

Is compoundedsemaglutidestill available The extensive semaglutide shortage that has impacted patients and healthcare providers for a significant period has officially ended. On February 21, 2025, the U.S. Food and Drug Administration (FDA) declared that the shortage of semaglutide injection products has been resolved. This pivotal announcement signifies a major shift in the availability of popular GLP-1 medications, including Ozempic and Wegovy, both of which are chemically known as semaglutide.Did the FDA ban compounded semaglutide?

For a considerable time, the scarcity of these semaglutide medications led to widespread concern and a surge in the use of compounded versions. However, the FDA's declaration that the semaglutide shortage has been resolved means these semaglutide injection products from Novo Nordisk are now being continuously shipped and are meeting or exceeding expected U.S. demand. This means semaglutide is no longer in short supply in its FDA-approved forms. The previous assertion that there was no shortage is now a reality.

The End of Compounded Semaglutide Sales

One of the most significant implications of the resolved semaglutide shortage is the phasing out of compounded versions of the drug. These less expensive, off-brand alternatives were permitted by the FDA during the shortage period as an interim solution.2025年6月4日—A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many ... However, with the official resolution, compounding pharmacies can no longer make and sell semaglutide injections after a grace period. Federal deadlines have been set, and by specific dates, such as May 22, 2025, and Thursday (referring to the deadline following the FDA's announcement), these compounded versions must be out of the market.

This directive means that many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs.Novo Nordisk's Wegovy, Ozempic No Longer in Short ... The FDA has taken action, leading to cease-and-desist letters from manufacturers like Novo Nordisk and Eli Lilly. Consequently, the sale of compounded versions of some weight loss medications like Ozempic and Zepbound has been halted or is in the process of being restricted. The era of compounded semaglutide being readily available is drawing to a close, with the FDA’s removal of semaglutide from the drug shortage list in February 2025 being the catalyst.Novo Nordisk's Wegovy, Ozempic No Longer in Short ...

What This Means for Patients and the Future of GLP-1 Medications

For patients who rely on semaglutide for managing their diabetes or for weight loss, the end of the shortage means greater access to the authentic, FDA-approved medications.Semaglutide was officially declared to no longer be on shortageby the FDA this morning. Compounding pharmacies that are compounding copies of the commercial ... The supply of the only real, FDA-approved semaglutide medicines is resolved, ensuring that patients can obtain their prescribed treatments without the uncertainty of shortages. This also implies that the semaglutide shortage has officially ended in the U.Semaglutide was officially declared to no longer be on shortageby the FDA this morning. Compounding pharmacies that are compounding copies of the commercial ...S., leading to significant changes in the GLP-1 drug industry.

The FDA's clarification of its policies for compounders, following the end of the semaglutide shortage over, marks a definitive step. While some may inquire about why compounded tirzepatide actions are different or if compounded semaglutide is still available, the general consensus is that the market for these copycat versions is significantly diminishing. Pharmacists do not believe that compounded GLP-1s will disappear completely, but their availability and legality are now under much stricter scrutiny, especially in the absence of an official shortage.End of Semaglutide Shortage Means Big Changes for ...

The surge in prescriptions for semaglutide for weight loss was a contributing factor to the global supply issues.FDA's Removal of Semaglutide and the Evolving ... Now that the supply chain is stabilizing, the focus shifts back to the approved indications and responsible prescription practices. While some companies may explore alternatives to compounded semaglutide, the primary path forward involves accessing the FDA-approved semaglutide products.

It's important to note that the FDA has also warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, or retatrutide that are falsely labeledOur response to serious supply issues of drugs for people .... These actions are a critical part of ensuring patient safety and drug integrity.

In conclusion, the semaglutide shortage has officially ended in the US, bringing relief to manyThe next pharma patent cliff: how 2026-2032 will reshape revenue. While the landscape of GLP-1 medications is evolving, the resolution of the shortage ensures greater accessibility to semaglutide for those who need it, while also bringing regulated clarity to the market concerning compounded alternatives2025年4月11日—The FDA recently declared an end to the nationwide shortage of their active ingredients,semaglutideand tirzepatide. During the shortage, .... The era of the semaglutide shortage is over, and the industry is now navigating a new phase of availability and regulation.